Tanja Pejovic, MD
Gynecologic Oncology · Portland, ORNPI 1770598278
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,583 of the $16,718 with a category attached, or 81.2%. 14 manufacturers reported payments, led by AstraZeneca at 42.2% of the total. 2025 is the largest year on record at $5,387, 2.4 times the $2,260 reported in 2019.
Across 48 payments — averaging $348.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$7K
- GSK$4K
- Merck$2K
- Eisai Inc.$2K
- Merz North America, Inc.$446
- Immunogen, Inc.$267
- plus $829 from 8 others
What the payments were for
- Consulting fees$13,58381%
- Travel & lodging$8935%
- Food & beverage$2,15213%
- Education$911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $7,052 |
| GSK | 5 | $3,787 |
| Merck | 1 | $2,440 |
| Eisai Inc. | 2 | $1,898 |
| Merz North America, Inc. | 7 | $446 |
| Immunogen, Inc. | 3 | $267 |
| Modernatx, Inc. | 1 | $250 |
| AbbVie | 3 | $219 |
| Myriad Genetic Laboratories, Inc. | 1 | $106 |
| Caris MPI, Inc. | 1 | $101 |
| Pfizer | 2 | $55 |
| Clovis Oncology, Inc. | 3 | $50 |
| Biogen | 1 | $27 |
| Coopersurgical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,718 in reported general payments places this provider in the 80th percentile of 25 gynecologic oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine | 15 | $569 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Portland
- Christopher DarusPortland$24K
- Gina WesthoffPortland$16K
- Kathryn McGoniglePortland$9K
- Elizabeth MunroPortland$8K
- Amanda BrueglPortland$5K
- Amanda CompadrePortland$3K
- Erin SalinasPortland$3K
- Breana HillPortland$3K
- Jenna EmersonPortland$2K
- Jessica JouPortland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.